{
    "clinical_study": {
        "@rank": "75579", 
        "arm_group": {
            "arm_group_label": "Suspected or known CAD", 
            "arm_group_type": "Other", 
            "description": "Myocardial Perfusion MRI with administration of gadolinium contrast(Optimark\u00ae)and vasodilator(regadenoson used off-label)"
        }, 
        "brief_summary": {
            "textblock": "This is a pilot study in a patient population with suspected Coronary Artery Disease CAD) as\n      defined by the presence of an abnormal nuclear (PET/SPECT) perfusion scan. In this study\n      design, PET/SPECT will serve as the comparative standard for presence of myocardial\n      ischemia. We intend to determine the accuracy of a novel MR technique for localization of\n      perfusion deficits in comparison to PET/SPECT.\n\n      This is not a study to specifically evaluate the efficacy or safety of the drugs but rather\n      the diagnostic accuracy of the cardiac MRI procedure as a whole"
        }, 
        "brief_title": "Artifact-Free High-Resolution Myocardial Perfusion MRI in Subjects With Abnormal Nuclear Myocardial Perfusion Studies", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Coronary Artery Disease", 
            "CAD"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease"
            ]
        }, 
        "detailed_description": {
            "textblock": "A total of 2 imaging protocols will be used in this study: (1) One-day SPECT protocol, which\n      involves the subjects undergoing stress myocardial perfusion SPECT and MRI in the same day;\n      (2) Two-day PET/SPECT protocol, which involves MRI of subjects who have had a recent\n      abnormal PET/SPECT study and includes an optional second-day visit.\n\n      Two blinded readers will interpret MR and SPECT/PET studies by consensus to assess the\n      presence of perfusion deficits at stress and rest."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adults \u2265 18 years of age\n\n          -  Clinically stable individuals with suspected or known coronary artery disease\n\n          -  Clinically indicated stress PET/SPECT study with mild to moderate ischemia or prior\n             myocardial infarction AND a visual scan interpretation of definitely abnormal; or,\n             clinically indicated stress SPECT study with either prior myocardial infarction or\n             prior abnormal SPECT/PET study and no intervening revascularization since the prior\n             study.\n\n        Exclusion Criteria:\n\n          -  Hypotension (systolic blood pressure <100 mm Hg)\n\n          -  Significant non-coronary cardiac disease (e.g. severe valvular abnormality,\n             significant cardiomyopathy, etc).\n\n          -  Persons unable to successfully pass MRI health and safety screening\n\n          -  Persons whose renal function test does not meet CSMC standard of care MRI contrast\n             protocol requirements (GFR <45 ml/min based on serum creatinine, age, gender, and\n             ethnicity).\n\n          -  Subjects with contraindications to or intolerance of regadenoson.\n\n          -  Persons with an allergy to gadolinium-based contrast.\n\n          -  Persons with a history of kidney or liver disease."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "44", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01949844", 
            "org_study_id": "28466"
        }, 
        "intervention": [
            {
                "arm_group_label": "Suspected or known CAD", 
                "description": "Lexiscan\u00ae is being used off-label. The FDA Issued IND # is 119898.  For the cardiac MRI, Lexiscan\u00ae will be used at the same dosage and administration as prescribed in the package insert - 5 mL (0.4 mg regadenoson) as packaged and supplied by the manufacturer, Astellas Pharma U.S., in single-use pre-filled syringes administered by rapid intravenous injection, followed immediately by saline flush.", 
                "intervention_name": "regadenoson", 
                "intervention_type": "Drug", 
                "other_name": "Lexiscan\u00ae"
            }, 
            {
                "arm_group_label": "Suspected or known CAD", 
                "description": "For the cardiac MR, the contrast agent, Optimark\u00ae is administered as a bolus peripheral intravenous injection at a dose of 0.2 mL/kg (0.1 mmol/kg) and at a rate of 1 to 2 mL/sec delivered by manual injection.", 
                "intervention_name": "Optimark\u00ae", 
                "intervention_type": "Drug", 
                "other_name": [
                    "gadoversetamide", 
                    "gadolinium", 
                    "MRI contrast agent", 
                    "gadolinium contrast"
                ]
            }, 
            {
                "arm_group_label": "Suspected or known CAD", 
                "description": ".", 
                "intervention_name": "Myocardial perfusion MRI", 
                "intervention_type": "Device", 
                "other_name": [
                    "magentic resonance imaging", 
                    "ischemia", 
                    "cardiac blood flow", 
                    "perfusion"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Regadenoson"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "MRI", 
            "Magnetic Resonance Imaging", 
            "myocardial perfusion", 
            "myocardial perfusion imaging", 
            "Novel MRI Techniques"
        ], 
        "lastchanged_date": "April 4, 2014", 
        "location": {
            "contact": {
                "email": "behzad.sharif@cshs.org", 
                "last_name": "Behzad Sharif, PhD", 
                "phone": "310-423-7758"
            }, 
            "facility": {
                "address": {
                    "city": "Los Angeles", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "90048"
                }, 
                "name": "Cedars-Sinai Medical Center"
            }, 
            "investigator": {
                "last_name": "Daniel S Berman, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Artifact-Free High-resolution Myocardial Perfusion MRI in Subjects With Abnormal Nuclear Myocardial Perfusion Studies", 
        "overall_contact": {
            "email": "behzad.sharif@cshs.org", 
            "last_name": "Behzad Sharif, PhD", 
            "phone": "310 423-7758"
        }, 
        "overall_contact_backup": {
            "email": "bermand@cshs.org", 
            "last_name": "Daniel S Berman, MD", 
            "phone": "310 423-4387"
        }, 
        "overall_official": {
            "affiliation": "Cedars-Sinai Medical Center", 
            "last_name": "Daniel S Berman, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Presence and severity of myocardial perfusion deficit on MR and PET/SPECT scans as assessed by blinded readers on a 4-point scale from none to severe.", 
            "measure": "Presence and severity of perfusion deficit on images", 
            "safety_issue": "No", 
            "time_frame": "baseline only"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01949844"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Cedars-Sinai Medical Center", 
            "investigator_full_name": "Daniel S. Berman", 
            "investigator_title": "Chief, Cardiac Imaging / Nuclear Cardiology", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "source": "Cedars-Sinai Medical Center", 
        "sponsors": {
            "collaborator": {
                "agency": "Astellas Pharma US, Inc.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Daniel S. Berman", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2012", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}